The cervix represents a formidable structural barrier for successful induction of labor. Approximately 10% of pregnancies undergo induction of cervical ripening and labor with prostaglandin (PG) E 2 or PGE analogs, often requiring many hours of hospitalization and monitoring. On the other hand, preterm cervical ripening in the second trimester predicts preterm birth. The regulatory mechanisms of this paradoxical function of the cervix are unknown. Here, we show that PGE 2 uses cell-specific EP2 receptor-mediated increases in Ca 2+ to dephosphorylate and translocate histone deacetylase 4 (HDAC4) to the nucleus for repression of 15-hydroxy prostaglandin dehydrogenase (15-PGDH). The crucial role of 15-PGDH in cervical ripening was confirmed in vivo. Although PGE 2 or 15-PGDH inhibitor alone did not alter gestational length, treatment with 15-PGDH inhibitor + PGE 2 or metabolism-resistant dimethyl-PGE 2 resulted in preterm cervical ripening and delivery in mice. The ability of PGE 2 to selectively autoamplify its own synthesis in stromal cells by signaling transcriptional repression of 15-PGDH elucidates long sought-after molecular mechanisms that govern PG action in the cervix. This report details unique mechanisms of action in the cervix and serves as a catalyst for (i) the use of 15-PGDH inhibitors to initiate or amplify low-dose PGE 2 -mediated cervical ripening or (ii) EP2 receptor antagonists, HDAC4 inhibitors, and 15-PGDH activators to prevent preterm cervical ripening and preterm birth.espite decades of clinical use for cervical ripening and induction of labor, mechanisms of prostaglandin (PG)-mediated cervical ripening are largely unknown. Likewise, it is not understood why some women at term respond to vaginal PGs for cervical ripening whereas others do not. Although failure rates vary depending on preparation, method of administration, definition of failure, dose, and dosing interval, in general the overall risk of the cervix remaining unchanged or unfavorable for induction of labor 12-24 h after vaginal PGs is 21.6% (1), which is consistent with a recent report in which 122 of 488 (25%) women failed to obtain a ripe cervix (as defined by Bishop Score < 7) after 4 PGE 2 (3 mg) tablets (2). Further, PGE 2 treatment leads to uterine hyperstimulation in 1-5.8%, of which 31% are associated with abnormalities in fetal heart rhythm (3). Both problems require emergency treatment and, in many cases, urgent operative delivery.Increased endogenous cervical PGs are derived from increased expression of the enzyme cyclooxygenase-2 (COX-2), which converts arachidonic acid to PGH 2 , which is then converted by PGE synthase (PTGES) to PGE 2 . Increases in cervical PGE 2 are prevented not only by low levels of COX-2 but also by high levels of the enzyme 15-prostaglandin dehydrogenase (15-PGDH) that inactivates PGE 2 by converting it to inactive 15-keto-PGE 2 (4-6). Hence, tissue levels of PGE 2 are regulated by the relative abundance of COX-2 and 15-PGDH enzymes. COX-2 levels increase in the cervix at term and in the myom...